2006
Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer
Pusztai L, Esteva FJ. Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer. Cancer Investigation 2006, 24: 187-191. PMID: 16619408, DOI: 10.1080/07357900500524629.Peer-Reviewed Original ResearchConceptsTrastuzumab therapyClinical trialsBreast cancerImportant unanswered clinical questionsLong-term side effectsContinuation of trastuzumabPrior trastuzumab therapyTrastuzumab-containing therapyUse of trastuzumabMetastatic breast cancerUnanswered clinical questionsPositive breast cancerRandomized clinical trialsTerm side effectsAccrue patientsMetastatic diseaseContinued administrationRandomized trialsControl armRegistry programDisease progressionClinical questionsSide effectsModest toxicityTrastuzumab
2005
Adjuvant therapy for breast cancer.
Hennessy B, Pusztai L. Adjuvant therapy for breast cancer. Minerva Obstetrics And Gynecology 2005, 57: 305-26. PMID: 16166938.Peer-Reviewed Original ResearchConceptsBreast cancerAromatase inhibitorsAdjuvant chemotherapyAdjuvant therapyHormonal therapyHormone receptor-positive breast cancerLymph node-positive breast cancerHormone receptor-positive cancersNode-positive breast cancerReceptor-positive breast cancerAdjuvant chemotherapy regimensAnthracycline-based regimenChemo-therapeutic treatmentsIncorporation of trastuzumabSingle best treatmentAdjuvant hormonal therapyOverall survival advantageUse of trastuzumabDose of cyclophosphamideLarge randomized studiesSchedule of administrationSubset of patientsReceptor-positive cancersRisk of relapseImportant clinical advance